bearish
Immunotech Biopharm (永泰生物) IPO: Behind the Curve in Cell Therapy
617 Views23 Jun 2020 15:57
Immunotech Biopharma, a cell therapy focused healthcare company, launched book building to raise up to USD 142 million to list in Hong Kong.
In our...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Immunotech (永泰生物) IPO Trading: Bifurcation of Book Coverage09 Jul 2020
- Immunotech Biopharm (永泰生物) IPO: Behind the Curve in Cell Therapy23 Jun 2020
- Immunotech Biopharm (永泰生物) IPO: Challenges for Cellular Immunotherapies05 Sep 2019
x